Mesoblast Limited (AU:MSB) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Mesoblast Limited has announced promising results from a Phase 3 trial indicating that its allogeneic cell therapy, Revascor, significantly improves survival rates and reduces major cardiovascular events in high-risk ischemic heart failure patients with inflammation. These findings, published in the European Journal of Heart Failure, highlight the potential for Revascor to address inflammation-related heart failure, offering a new treatment avenue beyond standard care. This development positions Mesoblast as a key player in the innovative treatment of chronic heart conditions.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
